Introduction
Aberrant modulation of gene expression at the transcriptional level is at the origin of numerous diseases. By disregulating cell growth and triggering cell proliferation, various oncoproteins carry out their biological functions as transcription factors, critically relying on their DNA-binding capacities. Artificial transcription inhibition or modification is possible via various approaches through different interfaces (Fig. 1) . Selective recognition between the reaction partners on the interface is essential for success. Truncated mimics that lack, for example, the activation domain while retaining the DNA-binding requirements might interfere with DNA-complexation of the malignant natural counterpart, disrupt transcriptional induction and ultimately suppress the oncogenic activity [1] [2] . This short review will treat
Artificial transcription factor mimics: gradual expansion of the chemical space
Fifty years after the milestone discovery of the Watson and Crick double-helical structure of DNA, the official completion of the Human Genome Project (HGP) in 2003 was another landmark event in the history of natural sciences [10, 11] . Multidisciplinary research at the interface of various disciplines became prerequisite to distill the flood of new information and reap maximum reward from the genome data. The nascent discipline of chemical biology approaches biological problems from the chemist's point of view and employs its ability to proficiently design, prepare and characterize tailor-made compounds, which can be subsequently applied to probe biological systems in highly-controlled, well-defined experiments (reviewed in [12] ). Organic synthesis occupies an indispensable position in the discovery process, enabling the craftful preparation of tailor-made conjugates, not limited by the genetic code or the strictures of the ribosomal machinery. Through sophisticated strategies, the rigorous control of molecular structure and function provides access to the vast expanse of chemical space [13] . The targets of chemistry research in these days are no longer restricted to small drug-like molecules. Much of the intellectual adventure and challenge has gradually converged with biology and the size of aimed compounds has steadily increased.
The activity, selectivity and stability of biopolymers become controllable, and they can be tailor-made like small organic compounds. Furthermore, chemical protein synthesis has enabled the systematic development of proteins with enhanced potency and specificity as candidate therapeutic agents [14] . Consequently eliciting a recent awareness within the pharmaceutical society for the unexplored opportunities of the generally ignored chemical space (GICS), medicinal chemists start thinking outside their Lipinski box [15] .
Despite the promising relevance of probing simplified peptide versions derived from natural protein counterparts, progress has been remarkably slow, failing to keep pace with the plethora of resolved complexes. The fragile balance between structural minimization and biophysical outcome impedes rational design of down-sized mimics, demanding devoted trialand-error tuning of empirical constraints. Small monomeric peptides can bind the major groove as α-helix, if the associated entropic penalties are compensated via preorganization (e). Hybrid conjugates of a tripyrrole sequence and a peptide monomer represent another strategy to cope with thermodynamics. The former module assists in the major groove recognition by the latter module which mimics either the atypical zinc finger, GAGA (f) or the basic region leucine zipper GCN4 (g). Furnishing genuine mimics of natural proteins, a final approach consists in the combination of several major groove binding peptides, such as homodimeric GCN4 (h) or heterodimeric cMycMax (i) sequences.
Minor Groove Recognition: synthetic polyamides
Dervans polyamides, based on the minor groove binder Distamycin A (Fig 2a) , can be regarded as peptides with each α-carbon replaced by a five membered ring (Fig 2d) . Natural Distamycine is a crescent shaped, small polyamide with three pyrrole (Py) rings that binds AT rich sequences in the minor groove selectively. Dervans group demonstrated that substituting pyrrole by imidazole (Im) and introducing hydroxypyrrole (Hp), it became possible to recognise all bases by a specific combination of two rings [16] . The genetic code was cracked.
As the Dervan peptides bind the minor groove in a 2:1 fashion, affinity could be further increased by linking two peptides.
Additional modifications introduce specific properties to the DNA binders. Fusing a polyarginine to the tripyrrole increases binding affinity and promotes nuclear uptake even though these small molecules are already relatively cell permeable [17] . Linkage of a Dervan peptide, binding in the regulating domain of a gene, with the activator domain of a transcription factor allows for selective transcriptional activation of that specific gene [18] .
Conjugation with a natural alkylating moiety, like CC-1065 or duocarmycin, enhances the efficiency and selectivity of the DNA alkylation and can be used for gene silencing, as alkylated coding regions cannot be read by RNA polymerase II [19, 20] . Except for the TATA box binding protein, most natural proteins bind in the major groove. Except for a few cases where major groove protein binding is inhibited by minor groove binding Dervan peptides [21] , the latter are unsuitable for blocking the protein-DNA interface, as it was shown that both can bind at the same time.
Ultimately, to uniquely distinguish a site in the three gigabase human genome, a recognition sequence of 16 base pairs is required. Although examples of polyamides that can realise this exist, mismatch sequences will probably not disrupt binding, due to the great binding affinity of such a single molecule-DNA binder [22] .
Major Groove Recognition: stabilised monomeric helices
The majority of well-characterized families of native DNA-binding proteins rely on recognition D-helices to make base contacts in the major groove. The overall shape and dimensions of an D-helix allow it to fit into the major groove in a number of related, but significantly different ways. This variability explains the preference of natural proteins for targeting this wider groove over the narrower minor one.
The design of peptides mimicking the DNA binding domain of such proteins is not straightforward, as most α-helices lose the capability to fold and thus bind DNA with high affinity when removed from their natural context.
Various possible strategies have been described [23 and references cited therein] and consist
in the use of peptide fragments that stabilise an α-helix (Fig 2e) . Successfull substitution of non-crucial amino acids with the helix promoting alanine can be achieved. Helical structures can also be stapled by the formation of a lactam bridge between lysine and aspartic acid, four positions further in the chain. Alternatively one can make use of stable α-helices, as in the small, well-folded avian pancreatic polypeptide, where an α-helix is stabilised by hydrophobic interactions on one side of the helix. The other side of this helix can then be used to graft residues required for DNA recognition and binding.
Exploitation of minor groove conjugation for major groove recognition
It was shown that the covalent attachment of peptides to the DNA backbone through a linker can compensate for the entropic cost associated with secondary structure formation and bind DNA as an α-helix. Next to intramolecular binding to increase the affinity for DNA, cooperative binding is another option [23 and references cited therein]. This can be achieved by fusing intercalators or Dervan peptides to the major groove binding peptide (Fig 2f and   2g ). Combining different smaller DNA binding units, overall binding selectivity can be significantly improved.
Engineered Zinc Fingers: gripping the major groove
In the area of zinc finger transcription factors, an advanced level of insight and pairing control has been achieved [24] . Whereas other DNA-binding proteins generally make use of the twofold symmetry of the double helix, zinc fingers are linearly linked in tandem to recognize DNA stretches of varying lengths, with high discrimination fidelity. The ability to bind specifically to virtually any given DNA sequence, combined with the potential of fusing polydactyl zinc finger peptides with effector domains, has led to the technology of engineering of chimeric DNA modifying enzymes (equipped with e.g. methylase, nuclease or recombinase modules) and transcription factors (simple blockage without effector, repression vs. activation domains, and chromatin remodeling factors as examples) [25] . Opening the possibility of using the engineered zinc finger-based factors as novel human therapeutics, ongoing successes stimulated the creation of the first biotech companies to exploit this new platform (Sangamo BioSciences, Inc., in Richmond, California; and later Gendaq Ltd., as a spin-off of the MRC Laboratory of Molecular Biology, Cambridge, UK). Interestingly, customized zinc finger constructs for given DNA sequences can now be acquired commercially form Sigma-Aldrich, branded as Compo-Zr technology. Table 1 includes an example of a Zinc finger construct for therapeutic application. Although a vital sequel in the gradual expansion of the chemical space covering artificial transcription factors, most (if not all) zinc finger designs are biotechnologically-engineered and as such beyond the scope of present overview, emphasizing on miniature constructs synthesized via bottom-up organic synthesis. Despite numerous further studies and applications, ranging from genome annotation tools to (pre-)clinical implementation, the interested reader is therefore referred to excellent reviews recently disclosed in literature [26, 27] .
Artificial zipper miniatures seizing the major groove
The α-helical basic zipper (bZIP) and basic helix-loop-helix-zipper (b-HLH-ZIP) motifs are among the simplest protein structures able to bind the DNA major groove in a sequence- 
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Crosslinking methods in development
In order to block the protein-DNA interface, the above described mimics need to compete with the natural DNA-binding proteins. Capitalizing on previous successes at the proteinprotein interface, crosslinking moieties can be introduced to overcome the competition problem.
Exogenous bifunctional crosslinkers
For crosslinking purposes, it is most easy to add small reagents, like platina complexes, nitrogen mustards, psoralen or reactive aldehydes. In this case no modified DNA or protein is required and their size allows easy penetration in cell and nucleus. Most current chemotherapeutics belong to these compound classes and result in DNA intra-or interstrand crosslinking. The impact of covalent attachment of proteins was recognised more recently. It was shown that cisplatin, the best known anticancer drug, crosslinks nuclear matrix-bound transcription factors and cofactors to DNA [32] . The problem with these external reagents is their lack of selectivity. Selectivity can be dramatically increased by equipping either DNA or protein with reactive groups. Alternatively, incorporation of more selective photoactivatable crosslinking moieties has gained popularity. Over the years, an extensive collection of crosslinking techniques has been developed, mainly to study transient complexes between proteins or between proteins and DNA. Since it is not the intention of this paper to give an exhaustive list, the reader is referred to more specialised literature [33] [34] [35] . Table 2 intends to summarize the different chemical strategies for crosslinking.
DNA → Protein crosslinking
Many examples exist in which nucleotides are equipped with a reactive functionality, in order to form a covalent bond to a non-covalently bound protein. In first instance, it is possible to modify the phosphate backbone, for example with pyrophosphate internucleotide groups [36] or disulfide groups. In the last case a PSS-backbone (phosphorothiosulfide) is formed, which can break and further react selectively with protein cysteine groups. Cells treated with a PSSoligonucleotide of the binding site for NF-NB transcriptional factor underwent apoptosis [37] .
Secondly, nucleotide building blocks equipped with a reactive functionality (aldehyde, aziridine, alkylating moiety) can be used in automated DNA synthesis for the production of reactive oligonucleotides [38] . Additionally, various approaches for postsynthetic regioselective modification to introduce reactive functionalities into DNA have been described [39] . So called decoys, as depicted in Fig 1, have been developed for irreversible crosslinking and inhibition of transcription proteins [36] .
Protein → DNA crosslinking
As for crosslinking to DNA, strategies involving TFO (see Fig 1) for covalent blocking of the genome have been considered. Inhibition of transcription in cells was observed after application of a psoralen modified oligonucleotide and irradiation [40] .
Alternative approaches involving crosslinking peptides or proteins for achievement of covalent DNA blocking have received considerably less attention. The most straightforward way to introduce a crosslinking functionality in peptides or proteins involves cysteine side chain modification. This was described for determination of the orientation of a DNA binding motif within a complex [41] and later applied for determination of other DNA-protein complexes. Furthermore, unnatural reactive amino acids can be included during solution or solid phase peptide synthesis. Even in proteins unnatural amino acids can be introduced via the natural or mutated translation system [42, 43] . Recently a photoactivatable crosslinking protein, obtained by genetically encoding for a benzophenone containing amino acid was crosslinked to its DNA binding site [43] .
Although application of specifically engineered proteins for DNA crosslinking has thus proven feasible, the clear preference for the above described reverse approach can be explained in terms of the unpredictable influence of protein modification on DNA binding affinity. The DNA binding peptides described above, being potent candidates for mimicking their parent proteins, offer new possibilities in this area. As mentioned before, introduction of sequence selectivity to DNA targeting agents does improve their efficiency as anticancer drug. Following this trend, crosslinking transcription factor mimics might play an important role in future cancer treatment. [12] .
Harboring the potential to bridge fundamental academic aspirations with pharmaceutical 
